Anticoagulation for atrial fibrillation in heart failure patients:balancing between Scylla and Charybdis
Grigorios Tsigkas1
Anastasios Apostolos1
Stefanos Despotopoulos1
Georgios Vasilagkos1
Angeliki Papageorgiou1
Eleftherios Kallergis2
Georgios Leventopoulos1
Virginia Mplani1
Ioanna Koniari3
Dimitrios Velissaris4
John Parissis5
1.Department of Cardiology,University Hospital of Patras,Patras,Greece2.Department of Cardiology,University Hospital of Heraklion,Heraklion,Greece3.Department of Cardiology,University Hospital of South Manchester,NHS Foundation Trust,Manchester,United Kingdom4.Department of Internal Medicine,University Hospital of Patras,Patras,Greece5.Second Department of Cardiology,National and Kapodistrian University of Athens,Attikon University Hospital,Athens,Greece
摘要：The management of heart failure (HF) and atrial fibrillation (AF) in real-world practice remains a debating issue,while the number of HF patients with AF increase dramatically.While it is unclear if rhythm or rate control therapy is more bene-ficial and under which circumstances,anticoagulation therapy is the cornerstone of the AF-HF patients' approach.Vitamin-K ant-agonists were the gold-standard during the past,but currently their usage is limited in specific conditions.Non-vitamin K oral anticoagulants (NOACs) have gained ground during the last ten years and considered as gold-standard of a wide spectrum of HF phenotypes.The current manuscript aims to review the current literature regarding the indications and the optimal choice and usage of NOACs in HF patients with AF.
机标关键词：
论文发表日期：2021-05-28
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：10( 352-361 )